NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic), off-the-shelf, cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced it has received a $1.6M grant from the Office of Israel’s Chief Scientist (OCS). The grant is part of the Government’s Ministry of Trade and Industry Program to support innovative technologies in Israel. The $1.6M grant represents a 100% increase compared with the grant received by Pluristem from the OCS in the previous year. The funds will be designated to support the clinical trials of the Company as well as research and development activities.
